Prognostic factors in adenocarcinoma of the uterine cervix.
A group of 136 female patients with adenocarcinoma of the uterine cervix, treated at Memorial Sloan-Kettering Cancer Center between 1949 and 1981, with slides available for review, formed the basis for this study. They ranged in age from 10 to 91 years. Most (73%) had abnormal bleeding, either alone or in combination with other symptoms; 15% were asymptomatic. Eighty percent had a visible abnormality, most commonly an exophytic mass. Clinical stages were: 0 (3%), IB (61%), IIA (14%), IIB (10%), III (4%). There were four major histologic subtypes: mucinous (47%), endometrioid (24%), adenosquamous (15%), and clear cell (9%) carcinoma. Of the many clinicopathologic variables evaluated for prognosis, the most significant was stage of disease (P less than 0.0001). Those with Stage IB disease had a survival probability of 76% at 5 years compared with 49% for those with Stage IIA and 34% with Stage IIB. The endometrioid pattern was associated with a more favorable prognosis than any other histologic subtype (P = 0.02). The presence of lymphatic tumor emboli and/or metastatic carcinoma in any lymph node group was associated with a less favorable prognosis for patients with Stage IB and IIA disease (P less than 0.0001).
Saigo
P E
PE
Cain
J M
JM
Kim
W S
WS
Gaynor
J J
JJ
Johnson
K
K
Lewis
J L
JL
D000230:Adenocarcinoma / Q000209:etiology / Q000473:pathology* / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D002584:Cervix Uteri / Q000473:pathology; D002648:Child; D005260:Female; D006728:Hormones / Q000009:adverse effects; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D010298:Parity; D011379:Prognosis; D044469:Racial Groups; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D013194:Staining and Labeling; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000473:pathology* / Q000601:surgery; D014626:Vaginal Smears
D006728:Hormones